Risk increased by 13% relative to women never experiencing vasomotor symptoms.

Randomised study of olaratumab plus liposomal doxorubicin in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.

OS and toxicities were worse vs weekly paclitaxel.

Prospective cohort of 3446 women followed for nearly 21 years.

How can the concept of personalised medicine be applied in relation to cancer pain?

FDA also approved companion diagnostic test.

PARP inhibitors in recurrent ovarian cancer increase PFS. But if used more and more as first-line therapy, what will we do with PARP inhibitors in later lines?

In the past months there were several remarkable achievements in the field of cancer immunotherapy, the best example of science going from the bench to the bedside.

Primary PFI, platinum-based CT, and PARP-inhibitors strongly predict outcomes.

Pooled analysis shows 23.6-year elevated risk, peaking at 5 years postpartum.

Researchers have developed a spray which could prevent local and distant tumour recurrence after surgery.

Types other than HPV‐16/18 appear to have greater effect among women aged 30 and older.

Overall cancer risk boosted by 28%.

Active in advanced recurrent disease, with safety profile consistent vs other studies.